Drugs / Personalized cellular vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02808364 | Mar 2016 → Oct 2017 | glioblastoma | Guangdong 999 Brain Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02709616 | Mar 2016 → Oct 2017 | glioblastoma | Guangdong 999 Brain Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02808416 | Mar 2016 → Oct 2017 | metastatic malignant neoplasm in the brain | Guangdong 999 Brain Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized cellular vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02808416 ↗ |
| Modality | Cell therapy | “Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy.” NCT02709616 ↗ |
| Route | Intravenous | “The patients will be immunized i.d. and i.v. biweekly with DC cellular vaccines.” NCT02709616 ↗ |
| Route | Other | “The patients will be immunized i.d. and i.v. biweekly with DC cellular vaccines.” NCT02709616 ↗ |